Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
Shares of AbbVie (NYSE:ABBV) hit a session low on Tuesday as Reuters reported that UnitedHealth (NYSE:UNH) is removing the company's blockbuster therapy Humira from some of its formulary lists for ...
AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...
As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...
Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using adalimumab and each time you get a refill. Ask your health care professional how to prepare ...
A scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, was among a trio who received this year’s Nobel Prize in Chemistry.
Opens in a new tab or window Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic ...
European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...
Alvotech (ALVO), a commercial-stage global biotech company specializing in the development and manufacture of biosimilar medicines, ...
The company's immunology portfolio, particularly Skyrizi and Rinvoq, has been a key driver of growth, helping to offset the anticipated decline in Humira sales due to biosimilar competition.
The use of biologic-based therapeutics has revolutionized our ability to treat complex diseases such as cancer- and autoimmune-related disorders. Biologic-based therapeutics are known to generate anti ...